Vitamin D Deficiency Cut-Off
Vitamin D deficiency is defined as a serum 25-hydroxyvitamin D [25(OH)D] concentration below 50 nmol/L (20 ng/mL), though there is no universal consensus and different thresholds exist depending on the clinical context.
Defining Deficiency: The Evidence Landscape
The most authoritative guidance comes from the 2015 Endocrine Society, which defines vitamin D deficiency as serum 25(OH)D levels <50 nmol/L (<20 ng/mL) and insufficiency as 52.5 to 72.5 nmol/L (21 to 29 ng/mL) 1. This threshold is supported by the Institute of Medicine, which concluded that levels of 50 nmol/L or greater meet the needs of nearly all of the population 1.
However, the 2024 Endocrine Society guideline acknowledges ongoing uncertainty about optimal thresholds and emphasizes that associations between 25(OH)D levels and various health outcomes remain incompletely established 2. The U.S. Preventive Services Task Force explicitly states there is no consensus on how to define vitamin D deficiency and does not endorse a specific threshold 1.
Biochemical Evidence for Thresholds
Research provides some clarity on when physiologic abnormalities emerge:
At 25(OH)D <30 nmol/L (<12 ng/mL): A clear breakpoint exists where calcium, PTH, and alkaline phosphatase become abnormal 3. Among those below this threshold, 34.2% had elevated PTH, 6.1% had low calcium, and 6.1% had high alkaline phosphatase 3.
Between 30-75 nmol/L (12-30 ng/mL): No deleterious effects on bone mineral density, trabecular density, cortical porosity, or matrix mineralization density were found in this range, challenging the rationale for supplementation in "insufficient" individuals 3.
Optimal levels for mortality outcomes: Dose-response analyses in diabetic patients show the lowest risk for all-cause and cardiovascular mortality at approximately 60 nmol/L (24 ng/mL) 4.
Practical Clinical Thresholds
For General Population:
- Deficiency: <50 nmol/L (<20 ng/mL) - this is the most widely accepted threshold 1
- Severe deficiency: <30 nmol/L (<12 ng/mL) - where biochemical abnormalities consistently appear 3, 5
- Target level: ≥50 nmol/L (≥20 ng/mL) to meet population needs 1
For High-Risk Populations:
- Elderly/fracture prevention: Maintain ≥50 nmol/L to minimize fracture occurrence 5
- Diabetes patients: Target approximately 60 nmol/L for optimal mortality reduction 4
Important Caveats
Assay variability is a major limitation. The lack of standardized assays and internationally recognized reference standards means that reported values may vary significantly between laboratories 1. This can lead to both overdiagnosis (unnecessary treatment) and underdiagnosis (missed deficiency) 1.
Population-specific considerations matter. African Americans have paradoxically lower fracture rates despite higher prevalence of low vitamin D levels compared to white persons, suggesting that universal thresholds may not apply equally across all populations 1.
The 75 nmol/L (30 ng/mL) threshold for "insufficiency" lacks strong evidence. No plateau in PTH or other markers was found beyond this level, and no bone abnormalities were detected in individuals with levels between 30-75 nmol/L 3.
Screening Recommendations
The USPSTF concludes that evidence is insufficient to recommend population-wide screening for vitamin D deficiency in asymptomatic adults 1. The Endocrine Society recommends screening only in persons at risk, not at a population level 1.
Bottom line for clinical practice: Use 50 nmol/L (20 ng/mL) as the deficiency threshold when testing is clinically indicated in at-risk individuals. Levels below 30 nmol/L represent severe deficiency requiring treatment. Avoid routine screening in asymptomatic, low-risk adults 1.